Browsing by Author "Roffey, Darren M."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Effect of omega-3 fatty acids supplementation on adipokines: a systematic review and meta-analysis of randomized controlled trialsPublication . Sepidarkish, Mahdi; Rezamand, Gholamreza; Qorbani, Mostafa; Heydari, Hafez; Estêvão, M. Dulce; Omran, Dalia; Morvaridzadeh, Mojgan; Roffey, Darren M.; Farsi, Farnaz; Ebrahimi, Sara; Shokri, Fatemeh; Heshmati, JavadBackground Although a large body of literature reported the beneficial effects of omega-3 fatty acids (omega-3 FAs) consumption on adipokines levels, but recent findings from clinical trials are not univocal. The aim of this systematic review and meta-analysis was to evaluate the effect of omega-3 FAs supplements on adipokines. Methods We searched Medline, Web of Science, Scopus, Embase, and Cochrane Library from inception to August 2020 without any particular language limitations. Outcomes were summarized as standardized mean difference (SMD) with 95% confidence intervals (CIs) estimated from Hedge's g and random effects modeling. Results Fifty-two trials involving 4,568 participants were included. Omega-3 FAs intake was associated with a significant increase in plasma adiponectin levels (n = 43; 3,434 participants; SMD: 0.21, 95% CI: 0.04, 0.37; p = 0.01; I-2= 80.14%). This meta-analysis indicates that supplementing participants with omega-3 fatty acids more than 2000 mg daily and more than 10 weeks resulted in a significant and more favorable improvement in plasma adiponectin levels. However, omega-3 FAs intake had no significant effect on leptin levels (SMD: -0.02, 95% CI: -0.20, 0.17, I-2= 54.13%). Conclusion The evidence supports a beneficial effect of omega-3 FAs intake on serum adiponectin levels but does not appear to impact on leptin concentrations. Larger well-designed RCTs are still required to evaluate the effect of omega-3 FAs on leptin in specific diseases.
- Effects of vitamin D supplementation on bone health and bone-related parameters in HIV-infected patients: A systematic review and meta-analysisPublication . Rezamand, Gholamreza; Estêvão, M. Dulce; Morvaridzadeh, Mojgan; Akbari, Abolfazl; Tabaeian, Seidamir Pasha; Pizarro, Ana Beatriz; Malekahmadi, Mahsa; Hasani, Motahareh; Roffey, Darren M.; Mirzaei, Alireza; Heshmati, JavadPurpose: There is growing evidence that bone health is decreased in individuals with HIV infection. Vitamin D deficiency is also highly prevalent among HIV-infected patients. The literature was systematically reviewed to determine whether bone health and bone-related parameters may improve with vitamin D supplementation in HIV-infected individuals. Methods: Four databases were systematically searched for randomized clinical trials of vitamin D supplementation in HIV infection, published from January 1990 to September 2021. No language or publication restrictions were applied. Standardized mean differences (SMD) with 95% CIs are reported. A random-effects model was used to perform meta-analysis. Findings: Ten studies met the inclusion criteria (N = 733 participants at study completion). The mean ages of the patients in the included trials ranged from 10 to 49 years. The meta-analysis indicated that with vitamin D supplementation, serum 25-hydroxy vitamin D (25[OH]D) level was significantly increased (SMD, 1.86; 95% CI, 1.02 to 2.70; I-2 = 94.4%), but there were no significant effects on levels of serum 1,25-dihydroxy vitamin D (1,25-[OH](2)D) (SMD, 0.29; 95% CI, -0.07 to 0.64; I-2 = 67.4%), total bone mineral density (SMD, 0.07; 95% CI, -0.23 to 0.37; I-2 = 00.0%), spine bone mineral density (SMD, 0.15; 95% CI, -0.19 to 0.49; I-2 = 17.3%), and parathyroid hormone level (SMD, -0.18; 95% CI, -0.37 to 0.02; I-2 = 1.2%) in HIV-infected patients. (C) 2022 Elsevier Inc.